Home/Pipeline/ENDO-205

ENDO-205

Endometriosis

Phase 1Active

Key Facts

Indication

Endometriosis

Phase

Phase 1

Status

Active

Company

EndoCyclic Therapeutics

About EndoCyclic Therapeutics

EndoCyclic Therapeutics is pioneering a novel class of precision peptide therapeutics and diagnostics based on a platform technology that enables selective uptake and pH-sensitive activation within diseased cells. The company's pipeline is focused on high-need areas, including endometriosis, where it is advancing both a potential disease-modifying therapeutic (ENDO-205) and a non-invasive diagnostic (FemLUNA), as well as oncology programs. With an IND cleared for its lead candidate, EndoCyclic is positioned to address significant unmet medical needs with a targeted, non-hormonal approach that aims to avoid systemic toxicity.

View full company profile

Therapeutic Areas

Women's Health Oncology

Other Endometriosis Drugs

Drug	Company	Phase	Status
Promarker™Endo	Proteomics International	Late‑stage validation	Active
EV‑Endo	Cartherics	Preclinical	Active
Endometriosis Program	Cyclana Bio	Discovery	Active
Endometriosis Genetic Study	Juneau Biosciences	Discovery	Active
Potential Diagnostic Development	Juneau Biosciences	Research	Active
Endometriosis Discovery Program	Metri Bio	Discovery	Active
Endometriosis Test Suite	Heranova Lifesciences	Pre-clinical	Active
EndomTest	Kephera Diagnostics	Commercial (LDT)	Active
Undisclosed Immunotherapy	Apheon Bioscience	Preclinical	Active
FMC	FimmCyte	Pre-clinical	Active
ABC-201	Abcely	Preclinical	Active
ERβ Modulator Program	Cadenza Bio	Preclinical	Active